Swiss startup Atlas Bio secures $12.5M to tackle drug development's 70% failure rate. The funding, led by Creandum alongside First Momentum Ventures and LEA Partners, will support their innovative AI model for clinical trials.
Atlas Bio launched from stealth with a $10 million Seed round and an unannounced pre-Seed round, bringing total funding to $12.5 million. The startup aims to improve drug development by developing a unique AI model for in silico clinical trials. This approach seeks to reduce costs and failure rates in clinical trials. Atlas Bio's technology could revolutionize the way drugs are tested and developed.
Who to call at Atlas Bio, and when
A new round usually means Atlas Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Atlas Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Atlas Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atlas Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Atlas Bio
Location
Switzerland
About
Atlas Bio is a Swiss tech-bio firm that focuses on developing a foundational AI model to run in silico clinical trials. This innovative approach aims to tackle the high failure rate in drug development and replace traditional animal testing with human-relevant evidence. The company seeks to improve clinical trial design and de-risk the development process by simulating drug efficacy and safety signals before Phase II trials. Founded in 2024, Atlas Bio is working with top pharmaceutical companies to revolutionize the drug development landscape.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atlas Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SwitzerlandBiotechnologyArtificial IntelligencePharmaceutical